



NextPharma Technologies Announces €2.4 Million Investment to Upgrade its Sterile Vial Area at its Belgian Facility, near Brussels.

Surrey, UK, 8th March, 2010 - NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotechnology industries, is pleased to announce that it has invested €2.4 million towards the upgrade of its Sterile Vial Area (SVA) in Braine-l'Alleud, near Brussels in Belgium.

The newly established SVA for both solution and lyophilized vials, which is estimated to be operational by the end of 2010, will complement existing sterile capabilities at the Braine-l'Alleud facility covering ampoules, eye drops and cytostatics in vials (both solution and lyophilized forms). This additional capability will provide customers with an integrated solution for their non cytotoxic products from development in the Braine l'Alleud Sterile Product Development Center (SPDC) or at NextPharma's San Diego, US based development center to commercial production scale up at NextPharma's Braine-l'Alleud manufacturing facilities.

Dr Hermann Osterwald, Managing Director, NextPharma Technologies, Contract Manufacturing Services commented: "The completion of the SVA became a priority for our Braine facility following the successful completion of the SPDC and considerable interest from our customers. NextPharma's strategy for our Braine-l'Alleud facility has been to develop it as a centre of excellence for sterile development and manufacturing, (both cytostatic and non-cytostatic, including biologics). The recent completion of the SPDC, our rapidly growing development center in San Diego and now the SVA represent a key element of this strategy".

NextPharma's facility at Braine l'Alleud, Belgium has extensive know how in cytotoxics, lyophilization and solutions – gained over nearly twenty years in formulation development, manufacturing, packaging and control of cytotoxic products. NextPharma has initiated a programme for the implementation of FDA status, including extensive expansion and upgrading of its cytotoxics production

capacity and capabilities. Additionally, it has a keen focus on the development of new delivery dosage forms.

NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers including solids, liquids and semi-solid dosage forms, antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing (lyophilized and liquid fill), with particular expertise in product development and manufacture of oncology medicines.

-Ends-

Contact:

Dr. Hermann Osterwald

Managing Director CMS

NextPharma

Tel +49 551 382 105

Mobile: +49 171 558 969 0

Email: hermann.osterwald@nextpharma.de

www.nextpharma.com

Bill Wedlake

Chief Executive Officer

NextPharma Technologies Holding Limited

Tel +44 (0) 1483 479 121

www.nextpharma.com

Notes to Editors:

About NextPharma

NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry.

We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing. We are a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled drugs. Our sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules. Additionally we have significant expertise in paediatric drug formulation, development and manufacture. NextPharma offers 'one-stop' logistics solutions tailored to meet the needs of the global pharmaceutical industry under the rigid standards of cGSP/GDP regulations.

We operate globally with seven product development centres, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan.

We have 1,200 employees dedicated to serving over 200 customers world wide and a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.

We have a proven track record in almost all pharmaceutical technologies and product forms and in addition to the specialist areas above have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.

All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.